CLSA opined in its research report that comments from US President Donald Trump regarding drug pricing had reignited market volatility.In CLSA's opinion, the multi-payer structure of the US healthcare system limits the government's power to set prices, and any meaningful reform would impact a wide range of stakeholders, making actual implementation highly uncertain.Related NewsM Stanley's Latest OW Stocks w/ Top-ranked MOST Scores in APAC by Sectors (Table)While concerns are mounting over peak sales of overseas products, the US remains an incremental market for Chinese companies. In addition, China's policy environment is becoming more supportive, which is especially manifested in a more relaxed approach to drug pricing.CLSA has increased its basket allocation on leading pharma companies, including CSPC PHARMA (01093.HK) +0.200 (+3.503%) Short selling $69.59M; Ratio 20.958% , HANSOH PHARMA (03692.HK) +0.800 (+3.540%) Short selling $30.76M; Ratio 19.105% , and Hengrui (600276.SH) +0.160 (+0.298%) . With the easing of US-China trade tensions, it has also raised its allocation on WUXI APPTEC (02359.HK) -0.200 (-0.313%) Short selling $23.94M; Ratio 32.557% .(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-16 12:25.) (A Shares quote is delayed for at least 15 mins.)